**Brain Cancer Clinical Trials**

**UCI 10-10**
Collecting Brain Tumor Specimens for Glioma Vaccine (Bota)

**UCI 12-18**
Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments (Bota)

**EAF151**
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab In Patients with Recurrent Glioblastoma (Chow)

---

**ACOSOG A221101**
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme (Carrillo)

**UCI 15-79**
Phase II Open-label randomized study of radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 brain metastases from NSCLC (Carrillo)

**UCI 16-74**
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)

---

**SYMPTOM MANAGEMENT**

---

**CORRELATIVE**

---

**mets-SPECIFIC**

---

**opening soon**

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu 06/18
UCI 13-14
Randomized, Double-blind, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

ALLIANCE-A071401
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations (Carrillo)

RTOG 3503
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (Kong)

UCI 16-55
Phase Ib, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma (Bota)

ECOG EAY131
Molecular Analysis for Therapy Choice – MATCH (Bota)

SWOG S1609
*Some cohorts suspended*
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Bota)

UCI 14-58**
Ph1, Multicenter, Open-Label, Dose Escalation, Combination Study Of Marizomib And Bevacizumab In Bevacizumab-Naive Subjects With GradeIV MG Followed By Ph2 Studies Of Single Agent MRZ And Combination MRZ And Bevacizumab, And Ph1 Dose-Escalation Study Of Enterally-Administered MRZ With Bevacizumab. Bota

UCI 17-15**
Phase II Trial Of AV-GBM-1 As An Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation In Patients With Newly Diagnosed Glioblastoma Bota

ALLIANCE-A071601**
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Carrillo)

UCI 17-115**
Phase II Trial Of AV-GBM-1 As An Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation In Patients With Newly Diagnosed Glioblastoma Bota

ALLIANCE-A071601**
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Carrillo)

UCI 16-56**
Ph II Study of Optune in Bevacizumab-Naive Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

ALLIANCE-A071601**
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Carrillo)

UCI 17-88**
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with RT and TMZ in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (Bota)

UCI 17-115**
Phase II Trial Of AV-GBM-1 As An Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation In Patients With Newly Diagnosed Glioblastoma Bota

ALLIANCE-A071601**
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Carrillo)

UCI 16-56**
Ph II Study of Optune in Bevacizumab-Naive Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

ALLIANCE-A071601**
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Carrillo)

UCI 17-88**
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with RT and TMZ in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (Bota)

UCI 17-88**
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with RT and TMZ in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (Bota)

UCI 15-35
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)